Moderna Quarterly Cash Flow Statement
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 227.79 +1.24%
Moderna free cash flow
In the quarter ended Jun 30, 2026, Moderna generated -$526.0 million of operating cash flow and spent $37.0 million on capital expenditures. That left free cash flow of -$563.0 million, a free-cash-flow margin of -388.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Moderna cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -782.00M | -1.34B | -826.00M | -200.00M | -825.00M | -971.00M | -1.12B | 13.00M | -1.28B | -1.18B | 217.00M | -3.63B |
| Net Income growth (YoY) | — | — | — | -1638.46% | — | — | -616.13% | — | — | -1587.34% | -85.19% | -448.03% |
| Depreciation & Amortization | 56.00M | 56.00M | 66.00M | 51.00M | 56.00M | 38.00M | 59.00M | 51.00M | 40.00M | 35.00M | 203.00M | 246.00M |
| Stock-Based Compensation | 120.00M | 104.00M | 113.00M | 125.00M | 130.00M | 115.00M | 104.00M | 112.00M | 112.00M | 101.00M | 79.00M | 77.00M |
| Change in Working Capital | 66.00M | 85.00M | 1.36B | -1.02B | -288.00M | 166.00M | 1.70B | -1.78B | -33.00M | 448.00M | 1.49B | -468.00M |
| Operating Cash Flow | -526.00M | -630.00M | 930.00M | -847.00M | -919.00M | -1.04B | 825.00M | -1.57B | -1.27B | -989.00M | 622.00M | -1.60B |
| Capital Expenditures | -37.00M | -62.00M | -39.00M | -33.00M | -3.00M | -117.00M | -522.00M | -151.00M | -182.00M | -196.00M | -220.00M | -140.00M |
| Investing Cash Flow | 329.00M | -76.00M | -48.00M | 700.00M | 564.00M | 730.00M | -539.00M | 721.00M | 1.65B | 118.00M | -538.00M | 789.00M |
| Share Repurchases | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 1.00M |
| Financing Cash Flow | 14.00M | 17.00M | 581.00M | -1.00M | 9.00M | 4.00M | -3.00M | 11.00M | 34.00M | 14.00M | -109.00M | -58.00M |
| Net Change in Cash | -185.00M | -688.00M | 1.46B | -147.00M | -345.00M | -303.00M | 282.00M | -833.00M | 409.00M | -857.00M | -25.00M | -869.00M |
| Free Cash Flow | -563.00M | -692.00M | 891.00M | -880.00M | -922.00M | -1.15B | 303.00M | -1.72B | -1.46B | -1.19B | 402.00M | -1.74B |
This table shows 12 quarterly periods of Moderna's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MRNA's reporting calendar. What is a cash flow statement?